

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Ashkenazi et al. Serial No.: 09/396,710 Filed: September 15, 1999 For: Apo-2 Receptor Antibodies</p>	<p>Group Art Unit: 1646 Examiner: C. Kaufman</p> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on February 13, 2001 <i>Diane L. Marschang</i> Diane L. Marschang</p>
--	---

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[x] **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

Applicants wish to advise the Examiner of the following co-pending U.S. patent applications which may relate to the subject matter disclosed and/or claimed in the instant application:

08/857,216 filed May 15, 1997; 09/079,029 filed May 14, 1998; 09/020,746 filed February 9, 1998; 09/096,637 filed June 12, 1998; and 09/329,633 filed June 10, 1999.

Another published PCT reference is listed on the attached revised Form PTO-1449 (Modified),

and a copy of that reference on PTO-1449 is supplied herewith.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,
GENENTECH, INC.

Date: February 13, 2001

By:

Diane L. Marschang

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE